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Abstract
Background Malignant transformation represents the natural evolution of diffuse low-grade gliomas (LGG). This is a 
catastrophic event, causing neurocognitive symptoms, intensified treatment and premature death. However, little is known 
concerning the spatial distribution of malignant transformation in patients with LGG.
Materials and methods Patients histopathological diagnosed with LGG and subsequent radiological malignant transforma-
tion were identified from two different institutions. We evaluated the spatial distribution of malignant transformation with 
(1) visual inspection and (2) segmentations of longitudinal tumor volumes. In (1) a radiological transformation site < 2 cm 
from the tumor on preceding MRI was defined local transformation. In (2) overlap with pretreatment volume after importa-
tion into a common space was defined as local transformation. With a centroid model we explored if there were particular 
patterns of transformations within relevant subgroups.
Results We included 43 patients in the clinical evaluation, and 36 patients had MRIs scans available for longitudinal seg-
mentations. Prior to malignant transformation, residual radiological tumor volumes were > 10 ml in 93% of patients. The 
transformation site was considered local in 91% of patients by clinical assessment. Patients treated with radiotherapy prior to 
transformation had somewhat lower rate of local transformations (83%). Based upon the segmentations, the transformation 
was local in 92%. We did not observe any particular pattern of transformations in examined molecular subgroups.
Conclusion Malignant transformation occurs locally and within the T2w hyperintensities in most patients. Although LGG 
is an infiltrating disease, this data conceptually strengthens the role of loco-regional treatments in patients with LGG.
Keywords Brain neoplasm · Glioma · Neurosurgery · Transformation · Treatment
Introduction
Diffuse low-grade gliomas WHO grade 2 (LGG) remain 
a challenging entity in neuro-oncology. These are slow-
growing tumors, with a median growth rate of approximately 
4 mm/year [1, 2]. In spite of often rather well-defined mar-
gins on MRI, tumor cells are present outside the radiologi-
cally visible tumor, making this an infiltrative disease [3, 
4]. At an unpredictable point of time, LGG speed of growth 
increases due to malignant transformation [5, 6]. Malignant 
transformation is a key clinical event and leads to intensified 
treatment, increased morbidity and premature death [7–9]. 
Consequently, successful effort to delay transformation is 
expected to significantly prolong life and preserve quality 
of life [10].
Compared to studies on recurrence in high-grade gliomas, 
[11–18] there are relatively few studies concerning patterns 
of transformation in LGG [19]. The in vivo growth in high-
grade gliomas as depicted by MRI tends to follow white 
matter tracts and spread is less likely to be perpendicular to 
white matter tracts [20]. Thus, it is also very likely that the 
malignant transformation in LGG is not random. Drawbacks 
of the LGG literature concerning transformations are that 
some papers are old (i.e. from the CT era), mix adults and 
children, mix grade I and II tumors, or do not clearly dif-
ferentiate progression from transformation (i.e. “treatment 
failure”) [21–24]. Nevertheless, a study of 11 malignant 
transformations, where radiotherapy with 1–3 cm margins 
was provided, demonstrated that malignant transformation 
occurred within the irradiated volume [23]. This finding was 
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repeated by two other small studies including 16 and 20 
patients with “treatment failures” [22, 24]. A recent review 
on the topic of progression in LGG pointed out that there are 
few studies, but following more aggressive therapy there is 
an impression that atypical and non-local progressions and 
recurrences more often are seen [19].
Detailed knowledge of patterns of malignant transforma-
tion can be useful when providing local and regional treat-
ment. Question remain whether extensive or even suprato-
tal surgical resection is a scientifically sound approach. For 
instance, supratotal resections does not make much sense 
if we remove brain unlikely to undergo transformation. 
Concerning radiotherapy, better knowledge of disease pro-
gression can help draw “biological” radiation fields or even 
provide a scientific ground whether a shift from photon to 
proton beam radiotherapy is justified. Finally, do the differ-
ent molecular subgroups have different patterns of trans-
formation? With this background we wanted to study the 
radiological progression and transformation pattern in more 
detail.
The aim of this study was to provide detailed data con-
cerning the radiological pattern of malignant transformation 
in LGG.
Methods
In this retrospective study, adult patients (18 years or older) 
with histopathological verified hemispheric diffuse LGG 
without any contrast enhancement on MRI at time of diag-
nosis were eligible for inclusion. The patients were recruited 
from two different institutions, with patients from University 
Hospital of North Norway included from 1999 through 2009, 
and at St. Olavs University Hospital from 1999 through 
2015. The surgical indications differed between institutions, 
but the follow-up regimens were similar, but not identical, as 
described elsewhere [25]. Some patients lacked preoperative 
images, but in the radiological report it was clearly stated 
in all cases there was no contrast enhancement. Since the 
clinical judgement was based upon the pre-transformation 
scan (see below), we included these patients for the clini-
cal interpretation. The earlier WHO classifications used in 
the clinical setting were updated to WHO 2016, as previ-
ously reported, in all patients with tissue available [8, 26]. 
In some patients were treated with radio- or chemotherapy 
before malignant transformation, but in no cases the reason 
for treatment was new contrast enhancement.
Malignant transformation
A radiological transformation was considered in the event 
of a new significant contrast enhancement where repeated 
scans, clinical course or histopathology from reoperation 
separated this from cases of pseudoprogression, radionecro-
sis or unspecific post-treatment changes due to for instance 
ischemia. To determine the spatial transformation, we relied 
on MRI findings. Thus, malignant histology from re-oper-
ation in the absence of enhancement was despite the trans-
formation excluded from analyses of the spatial distribution 
of transformation since we had no reliable data on biopsy 
location. Also, other measures that could be taken as signs 
of malignant transformation prior to contrast enhancement, 
such as for instance FET-PET, was not used in this study 
[27]. Such information would presumably affect the tim-
ing of malignant transformation, but we believe to a lesser 
degree influence the spatial information.
Spatial distributions
In terms of spatial distribution, we used one method with 
clinical judgement (A.S.J) with visual inspection and crude 
one-dimensional measures, and one method based on tumor 
volume segmentations. A radiological transformation 
site < 2 cm from the tumor on high-intensity T2w and/or 
FLAIR signal abnormalities on the pre-transformation MRI 
scan defined local transformation. Distant malignant trans-
formation was used if clearly separated (> 2 cm) from the 
high-signal abnormalities from the pre-transformation scan.
In the method with tumor volume segmentation, semi-
automatic segmentations were performed using the open 
source medical imaging platform 3D Slicer (version 4.8.1, 
www.slice r.org). A radiologist (H.K.B) performed preopera-
tive segmentations and the follow-up segmentations were 
performed by a neurosurgeon with extensive experience in 
radiological LGG assessment (A.S.J). First, we segmented 
the preoperative tumor volume using T2 or FLAIR MRI 
sequences. Next, we identified the scan where malignant 
transformation (i.e. new contrast enhancement) was detected 
and segmented the contrast enhancement using T1 with gad-
olinium enhancement. Then, we segmented the T2 or FLAIR 
volume from the scan prior to the scan where malignant 
transformation was detected. Together, these segmentations 
built the fundament to the processing pipeline as described 
below.
Processing pipeline
Key MRI scans being the pre-operative, pre-transforma-
tion, and transformation timepoints were selected, and to 
determine the relative locations of transformation sites they 
needed to appear in the same referential space. A process-
ing pipeline, illustrated in Fig. 1, was therefore developed 
to generate the results for each patient. As input, the pair 
of original images (i.e., pre-operative, pre-transformation, 
and transformation) and corresponding ground truth vol-
umes (original tumor, pre-transformation, transformation) 
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were used, shown as step 1 in Fig. 1. Then, the brain was 
automatically segmented using a neural network model pre-
trained with over 300 samples, shown as step 2 in Fig. 1. 
The neural network follows a U-Net architecture and has 
been implemented in Python using Keras and TensorFlow 
[28]. Using the brain segmentation, the skull was stripped 
before performing registration of the pre-transformation and 
transformation images (as long as the corresponding ground 
truth volumes) toward the pre-operative MRI volume. This 
process, illustrated as step 3 in Fig. 1, was performed using 
a symmetric diffeomorphic technique (named SyN) from the 
Advanced Normalization Tools [29]. In the end, the three 
volumes of interest were displayed in an overlap fashion over 
each MRI volumes, all expressed in the pre-operative MRI 
space, represented by step 4 in Fig. 1.
Statistics
In this study we provide only descriptive statistics. 
This was chosen since focus was to describe patterns of 
transformation.
Results
We included 43 patients with radiological transformation 
in this study and they are presented in Table 1 for an over-
view. All patients were used in the clinical interpretation, 
and we had 36 patients with available tumor segmentations 
where the preoperative volume served as a fundament (seven 
patients lacked preoperative digitalized MRI images and one 
patient had a pre-transformation MRI scan that was not pos-
sible to segment).
In 35/43 patients (81%) we had complete radiological his-
tory with preoperative scan, scan prior to transformation (or 
similar to preoperative scan if rapid transformation), and 
scan containing the transformation. We used this informa-
tion to visualize the progression and transformation, and we 
present a collage of patients with different types of tumor 
distributions in Fig. 2.
In Tables 2 and 3 we present characteristics relevant 
to the malignant transformation itself. We observed that 
39 patients (91%) had local recurrence according to clini-
cal interpretation. According to the segmentation overlay 
model, 33/36 patients (92%) had malignant transformation 
within the preoperative tumor T2w/FLAIR volume. These 
patients were all considered to have a local transformation 
based upon clinical judgement, however the one patient with 
combined distant and local malignant transformation in the 
clinical data was categorized as local transformation in the 
overlay model since there was an overlap of volumes. 
An overall representation of the relative location of the 
transformation inside the pre-operative tumoral volume is 
shown in Fig. 3. A simplified tumor volume is represented 
as a unitary cube, where the center of cube reflects the center 
of the tumor. The distance ratio between the centroid of the 
transformation volume (after registration) and the centroid 
of the preoperative tumor volume is computed and is repre-
sented as one colored dot in the figure. A central dot means 
a transformation happened in the middle of the pre-oper-
ative tumor, and a dot closer to the white edges means a 
transformation happening on the border of the pre-operative 
tumor. Overall, there were many transformations occurring 
in a central location with respect to the preoperative tumor 
volume. In Fig. 3, we also visualize transformation sites for 
Fig. 1  Overview of the processing pipeline to visualize all MRI vol-
umes for a same patient in the same space. The first row (P) repre-
sents the pre-operative MRI volume, the second row (PT) the pre-
transformation MRI volume, and the third row (T) the transformation 
MRI volume. The columns are describing for one patient: (1) the ini-
tial MRI volumes with manual tumor segmentation (red for pre-oper-
ative, green for pre-transformation and blue for transformation), (2) 
the automatic brain segmentation (in yellow) for skull stripping, (3) 
the results of the volume registration in the pre-operative space, (4) 
the post-registration tumor volumes overlap
Table 1  Baseline, tumor and treatment characteristics for all included 
patients (n = 43)
*n = 36 due to lack of digital preoperative MRI
Age, mean (SD) 45.2 (12.9)
Female, n (%) 18 (41)
Preoperative tumor volume in ml, median (Q1–Q3) 30 (9–61)*
Histopathology, n (%)
 Oligodendroglioma 12 (28)
 Astrocytoma IDH mut 16 (37)
 Astrocytoma IDH wt 13 (30)
 LGG, NOS 2 (5)
Surgical resection prior to transformation, n (%) 21 (49)
Chemotherapy prior to transformation, n (%) 14 (33)
Radiotherapy prior to transformation, n (%) 23 (54)
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the different molecular subgroups, but no obvious pattern 
was seen.
We further summarized the pattern of transformation 
(according to clinical judgement, n = 43) in molecular 
subgroups and in relation to therapy given. There was no 
obvious pattern in local versus distant transformation, but 
the group with radiotherapy had somewhat lower proportion 
of local transformation (83%).
Discussion
This study shows that malignant transformation of LGG 
most often occurs locally regardless of subgroups. We found 
no specific transformation patterns with respect to molecular 
subgroups or when separated by type of treatment. Although 
LGG is an infiltrative cancer and MRI is insensitive in terms 
of detecting the biological tumor volume, almost all cases 
of transformation do occur locally within or in close prox-
imity to previous areas of hyperintensities as seen in T2w 
sequences.
Tumor burden
Studies indicate an association between tumor size or size 
of tumor remnant and earlier malignant transformation [7, 
30–34]. The dose–response relationship of tumor size and 
malignant transformation in astrocytomas and oligoastrocy-
tomas was demonstrated by Shaw et al. where 28% recurred 
with < 1 cm of remnant, 88% where remnant was 1–2 cm 
and 100% if > 2 cm remnant [33]. For oligodendrogliomas, 
the dose response relationship was also present, but to lesser 
extent with 23%, 43% and 75% depending on largest diam-
eter of remnant. Of note, in the study from Shaw et al. the 
definition of progression was a clear increase in T2/FLAIR 
or contrast enhancement, and this differs from our definition 
focusing on the detrimental event of malignant transforma-
tion. Others have demonstrated that oligodendrogliomas are 
more likely to progress without malignant transformation 
[30, 35]. Since the existing literature is a mix of progression 
and transformation, the numbers would likely differ even 
Fig. 2  Different examples showcasing the pre-operative volume (in 
red), the pre-transformation volume (in green) and the transformation 
volume (in blue) on top of the pre-operative MRI volume (n = 35). 
Each row is representing a different patient, and each column is rep-
resenting a different view. First row; local transformation within pre-
operative volume. Second row; local transformation without overlap. 
Third row; local transformation with border overlap. Fourth row; dis-
tant transformation
Table 2  Characteristics of 
malignant transformation (MT) 
(n = 43)
*n = 42 due to volumetric analysis not possible in one of the pre-transformation scans
**n = 36 due to lack of digital preoperative MRI
Median volume of tumor in the pre-transformation MRI, ml (Q1–Q3) 40 (19–89)*
Tumor volume < 10 ml in pre-transformation MRI, n (%) 3/42 (7)*
Median months from pre-transformation MRI scan to MT (Q1–Q3) 5 (3–12)
Multifocal MT, n (%) 11 (26)
MT volume in ml, median (Q1–Q3) 1.4 (0.4–5.0)
Median months from first surgery until MT (Q1–Q3) 37 (13–70)
Clinical; local MT, n (%)
 Local (within 2 cm), n (%) 39 (91)
 Distant, n (%) 3 (7)
 Combined, n (%) 1 (2)
Model; MT within preoperative volume, n (%) 33/36 (92)**
Histopathological verified MT through new resection, n (%) 19 (44)
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more between astrocytomas and oligodendrogliomas if only 
malignant transformation was analyzed.
In the surgical literature several studies have reported that 
remnant less than 10–15 ml have a better prognosis [36, 37] 
although no visible postoperative remnant is clearly superior 
[38–40]. In our series, smaller residual tumor volumes than 
10 ml did not protect against transformation although it was 
seen in only 7% of cases. Also, in none of the patients trans-
formation occurred without any preceding T2 hyperintensi-
ties, albeit in almost 10% of cases the transformations were 
distant and seemingly unrelated to earlier T2w hyperintensi-
ties. This association with MRI defined volume and trans-
formation is further corroborated by a study that focused 
on recurrent surgery of a previous LGG, where in stable 
lesions being WHO grade II the median volume was 15.6 ml 
while for tumors with transformations to WHO grade III 
and grade IV the volumes were 30.9 ml and 69.7 ml volume 
respectively [34].
Spatial distribution
In perceived low-risk patients undergoing surgical resec-
tion with aim of gross-total removal, and where no adjuvant 
therapy was provided, the spatial distribution of progres-
sion was found to be within 2 cm from the resection cavity 
in 82% of cases, more than 2 cm away in 16% and 2% had 
truly distant progression [33]. In our cohort that was not a 
typical low-risk profile and being based partly upon histori-
cal data where biopsies where frequently performed [25], 
we observed a higher proportion of local progressions and 
transformations. In low-risk patients undergoing extensive 
resection the pattern of transformation may be somewhat 
different, as observed by others that more aggressive therapy 
leave room for more atypical and distant progression and 
transformation patterns in the longer-term [19]. We included 
only patients with radiological transformations, excluding 
patients with transformation based upon histopathology 
alone from reoperation without preceding change in MR 
phenotype. These surgical transformations are also local in 
origin, hence the vast majority of patients with LGG will 
present a local transformation. Overall, the patterns of dis-
tributions together with the volume associations mentioned 
above conceptually favor aggressive locoregional therapy, 
and presumably also repeated surgery whenever possible.
An early study from North et al. demonstrated that all 
treatment failures were within the radiation field when 
2–3  cm margin was used [21]. Similarly, Shaw et  al. 
described that all failures were within the radiation field 
[24]. Also, survival was not improved by more extensive 
fields such as whole brain radiotherapy [24]. We observed 
slightly more distant recurrences in the subgroup treated 
with radiotherapy prior to malignant transformation. This 
may be a survivor effect if radiotherapy to some degree pre-
vents local malignant transformation, and since there is no 
cure, transformations will therefore eventually more often be 
distant. A recent study in patients with anaplastic gliomas 
treated with intensity-modulated radiation therapy suggested 
that radiotherapy may prevent local recurrence. In that study, 
a relapse pattern with components of marginal and distant 
pattern were observed in 19% and 37%, respectively [41]. 
Table 3  Patterns of malignant transformation (MT) according to 
clinical judgement and according to the model using tumor volumes 
overlay for clinically relevant subgroups
When we used a model of malignant transformation with pre-trans-
formation images instead of pre-operative images, there were no rel-
evant differences in results (n = 43)
*MT denotes malignant transformation
Clinic: local MT Model: 
MT inside 
pre-op
Astrocytoma IDH wt, n/N (%) 13/13 (100) 13/13 (100)
Astrocytoma IDH mut, n/N (%) 14/16 (88) 10/11 (91)
Oligodendroglioma, n/N (%) 11/12 (92) 9/10 (90)
Chemotherapy prior to MT, n/N (%) 13/14 (93) 12/13 (92)
Radiotherapy prior to MT, n/N (%) 19/23 (83) 15/18 (83)
No resection prior to MT, n/N (%) 20/22 (91) 20/22 (91)
Resection prior to MT, n/N (%) 19/21 (91) 13/14 (93)
Fig. 3  Overall distribution of the relative position of the centroid 
of the transformation volume over the centroid of the pre-operative 
volume for the different molecular marker groups. The few distant 
transformations are excluded in this model (n = 3). White represents 
the borders of the unitary pre-operative volume, red represents oligo-
dendroglioma, green the IDH mut astrocytomas, and blue the IDH wt 
astrocytomas
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In our view, the majority of studies indicate that the major-
ity of progression and transformation follow a local pattern, 
and this can argue for proton-beam radiotherapy in patients 
with LGG. However, to date there is very limited clinical 
evidence [42]. It has been speculated if the more conformal 
field would create a risk for more distant recurrences. How-
ever, one very recent larger retrospective study found that 
most recurrences following proton beam-radiotherapy were 
indeed local, with only 12% being “out of field”, a com-
parable figure to our “distant” transformations [43]. Thus, 
the “dose-bath” beyond the targeted areas are perhaps not 
needed since most recurrences and transformations are local. 
That larger areas of the presumably functional brain more 
often receives no radiation based upon comparative proton 
plans, means also less risk in the longer-term for cognitive 
decline. This is potentially important as we otherwise can 
transform long-term treatment successes in terms of sur-
vival to long-term failures speaking of cognitive function 
and quality of life.
Molecular markers and patterns of radiological 
transformation
Previous studies of malignant transformation have not used 
the WHO 2016 classification, and this may affect results. 
One recent study on failures following radiotherapy in ana-
plastic gliomas demonstrated a distant pattern of failure in 
45% of IDH mutated patients compared to 25% in those with 
IDHwt [41]. In our study we had > 1/3 with IDH mutated 
astrocytomas and almost 30% molecularly defined oligo-
dendrogliomas, however we did not find any differences in 
patterns of recurrence with respect to the molecular profile 
of the tumors. However, across subgroups the most common 
pattern of transformation was local.
Limitations
Ideally all areas should have been sampled to verify malig-
nant transformation, although either new histopathology or 
the clinical course ensured that only patients with malig-
nant transformation were included (and not pseudoprogres-
sion). The T2/FLAIR volume at time of progression was 
segmented to illustrate the growth of the tumor and use this 
in relation to the newly developed contrast enhancement to 
demonstrate the tumor evolution. However, in some cases 
the T2w images showed the occurrence of gliosis follow-
ing surgery and hyperintensities in patients undergoing 
radiotherapy. In these cases, this volume is associated with 
inherent uncertainty. Also, even the intra-observer variabil-
ity in LGG segmentations can be significant [44]. The over-
lay segmentation model also holds some limitations when 
comparing with the preoperative volumes in patients under-
going resection, as the cavity may shrink/collapse causing 
areas outside the cavity to appear within the cavity perhaps 
increasing the proportion of recurrences within the preop-
erative tumor volume. Further, this study is not equipped to 
answer effectiveness of therapies and the sample size did 
not allow for comparisons for time to transformation. Also, 
the small sample limits the subgroup analyses. Finally, the 
centroid model can provide erroneous results in multifocal 
tumors.
Conclusion
We provide new data on malignant transformation in patients 
with LGG. Although the tumors are diffusely infiltrating 
brain tissue outside the radiological tumor, the catastrophic 
event of malignant transformation occurs locally in the vast 
majority of patients. Molecular subgroups exhibit the same 
patterns of transformation. Minimizing the dense tumor, 
as defined by hyperintensity in T2w images, may prolong 
time to transformation. This may explain the strong associa-
tion of extensive resections and survival, and conceptually 
strengthen the role of effective loco-regional treatments in 
patients with LGG.
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